Advances of exosome regulating‑FXR to repair inflammatory bowel disease (Review)
Muro P., Jing C., Qiao Y., Wang W., Wang B., Mao F.
Narrative Review on Autoimmune Research, published in Int J Mol Med (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Int J Mol Med (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40613233
- PMCID
- PMC12270395
- DOI
- 10.3892/ijmm.2025.5576
- Citations
- 2
Abstract (original English)
Inflammatory bowel disease (IBD), which encompasses ulcerative colitis and Crohn's disease, poses significant treatment difficulties because of its persistent course and underlying inflammatory mechanisms. Existing treatments primarily focus on alleviating symptoms, while novel biological drugs that target specific molecular pathways could address the root causes of the disease. One such pathway involves the farnesoid X receptor (FXR), a nuclear receptor essential for bile acid metabolism, intestinal homeostasis and modulation of inflammation. Activating FXR can reduce intestinal inflammation and improve gut barrier function, highlighting its potential as a treatment target for IBD. However, using synthetic agonists to directly activate FXR has drawbacks, including off‑target effects and limited effectiveness. Exosomes, tiny nanoscale vesicles involved in cell‑to‑cell communication, have emerged as promising therapeutic tools for regulating FXR signaling in IBD. Exosomes, particularly those derived from mesenchymal stem cells, can deliver bioactive molecules that promote FXR activation, reduce inflammation, and enhance tissue regeneration. The present review examines how exosomes regulate FXR signaling and their potential therapeutic use in IBD. It covers exosome biogenesis, therapeutic benefits and their molecular mechanisms in IBD.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ARandomized Controlled TrialPubMed
Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.
Randomized Controlled Trial with a reported sample of 283 on Autoimmune Research, published in Gastroenterology (2026) — summary generated from the PubMed abstract.
- 2026
- n = 283
Gastroenterology3 citations - Level ASystematic ReviewEurope PMC
Intraoperative Autologous Adipose-Derived Therapies and PRP as Add-On in the Surgical Treatment of Cryptoglandular and Crohn's Disease-Related Perianal Fistula-A Systematic Review
Systematic Review with a reported sample of 1017 on Autoimmune Research, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 1017
Bioengineering (Basel) - Level ASystematic ReviewEurope PMC
Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies
Systematic Review on Skin Aging, Chronic Inflammation, Autoimmune Research, published in Front Physiol (2026) — summary generated from the PubMed abstract.
- 2026
Front Physiol - Level ASystematic ReviewEurope PMC
Surgical interventions in inflammatory bowel disease: Indications, techniques, outcomes, and future directions
Systematic Review on Autoimmune Research, published in World J Gastrointest Pharmacol Ther (2026) — summary generated from the PubMed abstract.
- 2026
World J Gastrointest Pharmacol Ther - Level ASystematic ReviewEurope PMC
Management of Oro-Antral Communication: A Systemic Review of Diagnostic and Therapeutic Strategies
Systematic Review on Autoimmune Research, published in Diagnostics (Basel) (2025) — summary generated from the PubMed abstract.
- 2025
Diagnostics (Basel)5 citations